Prediction of pharmacokinetics of antibiotics in patients with end-stage renal disease

被引:3
|
作者
Tajima, Naoyuki
Nagashima, Satoru
Uematsu, Toshihiko
Torii, Hideki
Tajima, Masami
Hishida, Akira
Naganuma, Hideo
机构
[1] Sankyo Co Ltd, Clin Pharmacol & Biostat Dept, Shinagawa Ku, Tokyo 1408710, Japan
[2] Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan
[3] Shitoro Clin, Hamamatsu, Shizuoka 4328067, Japan
[4] Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan
关键词
prediction; pharmacokinetics; hemodialysis; end-stage renal disease (ESRD); antibiotic;
D O I
10.1248/bpb.29.1454
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A novel and convenient method to predict the pharmacokinetics of several kinds of antibiotic agents in patients with end-stage renal disease (ESRD) was examined based on the in vitro extraction ratios and pharmacokinetic parameters in healthy volunteers. The dializability of 17 antibiotic agents in 4% human serum albumin solution were determined using a high-performance hemodialytic membrane for clinical use. We assumed that the off-hemodialysis clearance approximated the non-renal clearance, while the on-hemodialysis clearance was considered to be sum of the off-hemodialysis clearance and the hemodialytic clearance. The estimated on- and off-hemodialysis clearances were compared with the ones observed in ESRD patients. In order to confirm the method prospectively, an in vivo pharmacokinetic study was performed in dogs with mercury chloride-induced experimental renal failure. The in vitro extraction ratios of 9 beta-lactams were broadly ranged from 10.9 to 75.6% depending on their physicochemical properties. In contrast, those of the other antibiotics were consistent with their chemical classes: 60.5-63.2% for fluoroquinolone, 48.8-51.1% for aminoglycoside and 18.7-25.6% for glycopeptide. Both the estimated on- and off-hemodialysis clearances of the 17 antibiotics coincided well with the observed values in the literature, regardless of their physicochemical and pharmacokinetic properties. The validity and applicability of this method to three cefems, cefmetazole, cefotaxime and cefoperazone, was prospectively confirmed in the animal study. In conclusion, this new method enables the prediction of the on- and off-hemodialysis clearances of several kinds of antibiotics in ESRD patients from minimal information of their pharmacokinetics in healthy subjects and their in vitro dializability.
引用
收藏
页码:1454 / 1459
页数:6
相关论文
共 50 条
  • [1] Pharmacokinetics of rosiglitazone in patients with end-stage renal disease
    Thompson-Culkin, K
    Zussman, B
    Miller, AK
    Freed, MI
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2002, 30 (04) : 391 - 399
  • [2] Nefopam Pharmacokinetics in Patients with End-Stage Renal Disease
    Mimoz, Olivier
    Chauvet, Stephane
    Gregoire, Nicolas
    Marchand, Sandrine
    Le Guern, Marie-Emmanuelle
    Saleh, Ashraf
    Couet, William
    Debaene, Bertrand
    Levy, Rene H.
    ANESTHESIA AND ANALGESIA, 2010, 111 (05): : 1146 - 1153
  • [3] The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis
    Don, BR
    Spin, G
    Nestorov, I
    Hutmacher, M
    Rose, A
    Kaysen, GA
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2005, 57 (11) : 1407 - 1413
  • [4] Pharmacokinetics of Intravenous Delafloxacin in Patients With End-Stage Renal Disease
    Hoover, Randall
    Alcorn, Harry, Jr.
    Lawrence, Laura
    Paulson, Susan K.
    Quintas, Megan
    Cammarata, Sue K.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (07): : 913 - 919
  • [5] PHARMACOKINETICS AND PHARMACODYNAMICS OF EVOGLIPTIN IN END-STAGE RENAL DISEASE PATIENTS ON HEMODIALYSIS
    Kim, B.
    Yu, K.
    Lee, S.
    Oh, J.
    Jang, I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S67 - S67
  • [6] THE PHARMACOKINETICS OF AMINOGUANIDINE IN END-STAGE RENAL-DISEASE PATIENTS ON HEMODIALYSIS
    FOOTE, EF
    LOOK, ZM
    GILES, P
    KEANE, WF
    HALSTENSON, CE
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (03) : 420 - 425
  • [7] Pharmacokinetics of Aliskiren in Patients with End-Stage Renal Disease Undergoing Haemodialysis
    Dmytro Khadzhynov
    Torsten Slowinski
    Ina Lieker
    Hans-Hellmut Neumayer
    Diego Albrecht
    Henk Johan Streefkerk
    Sam Rebello
    Harm Peters
    Clinical Pharmacokinetics, 2012, 51 : 661 - 669
  • [8] NETILMICIN AND TOBRAMYCIN PHARMACOKINETICS IN PATIENTS WITH END-STAGE RENAL-DISEASE
    MATZKE, GR
    HALSTENSON, CE
    ABRAHAM, PA
    MOONEY, JJ
    LORBER, RR
    KEANE, WF
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (02) : 258 - 258
  • [9] Prediction of quality of life in patients with end-stage renal disease
    Martin, CR
    Thompson, DR
    BRITISH JOURNAL OF HEALTH PSYCHOLOGY, 2000, 5 : 41 - 55
  • [10] Pharmacokinetics of Aliskiren in Patients with End-Stage Renal Disease Undergoing Haemodialysis
    Khadzhynov, Dmytro
    Slowinski, Torsten
    Lieker, Ina
    Neumayer, Hans-Hellmut
    Albrecht, Diego
    Streefkerk, Henk Johan
    Rebello, Sam
    Peters, Harm
    CLINICAL PHARMACOKINETICS, 2012, 51 (10) : 661 - 669